Edwards Lifesciences CorporationEWNYSE
Loading
Gross Profit Growth Under PressureDecelerating
Percentile Rank44
3Y CAGR+4.5%
5Y CAGR-20.3%
Year-over-Year Change
Year-over-year gross profit growth rate
3Y CAGR
+4.5%/yr
vs -13.2%/yr prior
5Y CAGR
-20.3%/yr
Recent acceleration
Acceleration
+17.7pp
Accelerating
Percentile
P44
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.60% |
| Q3 2025 | 1.68% |
| Q2 2025 | 7.07% |
| Q1 2025 | 1.60% |
| Q4 2024 | 0.19% |
| Q3 2024 | 0.31% |
| Q2 2024 | 4.56% |
| Q1 2024 | 2.48% |
| Q4 2023 | 4.55% |
| Q3 2023 | -5.22% |
| Q2 2023 | -6.87% |
| Q1 2023 | 4.52% |
| Q4 2022 | 1.41% |
| Q3 2022 | -4.60% |
| Q2 2022 | 5.18% |
| Q1 2022 | 1.57% |
| Q4 2021 | 0.92% |
| Q3 2021 | -3.88% |
| Q2 2021 | 13.06% |
| Q1 2021 | 3.57% |
| Q4 2020 | 5.00% |
| Q3 2020 | 25.75% |
| Q2 2020 | -20.80% |
| Q1 2020 | -2.41% |
| Q4 2019 | 11.40% |
| Q3 2019 | 2.23% |
| Q2 2019 | 2.39% |
| Q1 2019 | 1.63% |
| Q4 2018 | 8.04% |
| Q3 2018 | -3.37% |
| Q2 2018 | 7.17% |
| Q1 2018 | 1.42% |
| Q4 2017 | 7.98% |
| Q3 2017 | -4.39% |
| Q2 2017 | -4.88% |
| Q1 2017 | 19.38% |
| Q4 2016 | 2.97% |
| Q3 2016 | -2.78% |
| Q2 2016 | 7.70% |
| Q1 2016 | 4.40% |